Eisai and Biogen introduce Alzheimer's drug Leqembi in Chinese market

Eisai and Biogen Launch Alzheimer's Treatment in China

In a significant development, Eisai and Biogen have introduced their Alzheimer's medication, Leqembi, to the Chinese market, marking the third country where it’s available following releases in the United States and Japan. Leqembi is notable for its ability to remove beta amyloid, a toxic protein, from the brain, distinguishing it as the first Alzheimer's treatment that can fundamentally alter the progression of this devastating disease.

The initial rollout will target the private sector, with the drug priced at 2,508 yuan (approximately $345.04) per 200 mg vial. In addition, Eisai has entered into a collaboration with a leading Chinese medical insurance firm to facilitate partial coverage of the drug's cost, although the insurer's identity remains undisclosed.

Regulatory Approvals and Future Potential

China gave the green light to Leqembi in January, following its standard approval by the U.S. Food and Drug Administration last July. Looking ahead, the introduction of more accessible Alzheimer's blood tests by 2025 could enable Eisai to reach a larger segment of China’s estimated 17 million individuals in the early stages of the disease, as suggested by a company representative in a previous statement.

The significance of this launch cannot be overstated, as it represents a potentially transformative step forward in Alzheimer's treatment. By making Leqembi available in China, Eisai and Biogen are not only expanding their market reach but also offering new hope to millions affected by the disease.